Optimization of prednisolone-loaded long-circulating liposomes via application of Quality by Design (QbD) approach

Abstract Quality by design principles (QbD) were used to assist the formulation of prednisolone-loaded long-circulating liposomes (LCL-PLP) in order to gain a more comprehensive understanding of the preparation process. This approach enables us to improve the final product quality in terms of liposomal drug concentration, encapsulation efficiency and size, and to minimize preparation variability. A 19-run D-optimal experimental design was used to study the impact of the highest risk factors on PLP liposomal concentration (Y1- μg/ml), encapsulation efficiency (Y2-%) and size (Y3-nm). Out of six investigated factors, four of them were identified as critical parameters affecting the studied responses. PLP molar concentration and the molar ratio of DPPC to MPEG-2000-DSPE had a positive impact on both Y1 and Y2, while the rotation speed at the formation of the lipid film had a negative impact. Y3 was highly influenced by prednisolone molar concentration and extrusion temperature. The accuracy and robustness of the model was further on confirmed. The developed model was used to optimize the formulation of LCL-PLP for efficient accumulation of the drug to tumor tissue. The cytotoxicity of the optimized LCL-PLP on C26 murine colon carcinoma cells was assessed. LCL-PLP exerted significant anti-angiogenic and anti-inflammatory effects on M2 macrophages, affecting indirectly the C26 colon carcinoma cell proliferation and development.

[1]  J. Shaji,et al.  NANOCARRIERS FOR TARGETING IN INFLAMMATION , 2013 .

[2]  D. Muntean,et al.  QUERCETIN-LOADED LIPOSOMES: FORMULATION OPTIMIZATION THROUGH A D-OPTIMAL EXPERIMENTAL DESIGN , 2015 .

[3]  S. Gordon,et al.  The M1 and M2 paradigm of macrophage activation: time for reassessment , 2014, F1000prime reports.

[4]  R. Schiffelers,et al.  Antitumor activity and tumor localization of liposomal glucocorticoids in B16 melanoma-bearing mice. , 2008, Journal of controlled release : official journal of the Controlled Release Society.

[5]  Ziyaur Rahman,et al.  Understanding the quality of protein loaded PLGA nanoparticles variability by Plackett-Burman design. , 2010, International journal of pharmaceutics.

[6]  E. Licărete,et al.  Cytotoxicity of lipophilic statins depends on their combined actions on HIF-1&agr; expression and redox status in B16.F10 melanoma cells , 2014, Anti-cancer drugs.

[7]  Diane J Burgess,et al.  A quality by design (QbD) case study on liposomes containing hydrophilic API: I. Formulation, processing design and risk assessment. , 2011, International journal of pharmaceutics.

[8]  J. Foley Alternative Activation , 2008, Science Signaling.

[9]  S. Gordon,et al.  Alternative activation of macrophages: an immunologic functional perspective. , 2009, Annual review of immunology.

[10]  Lilli Møller Andersen,et al.  Quality Risk Management , 2021, Handbook of Pharmaceutical Manufacturing Formulations, Second Edition.

[11]  G. Gregoriadis,et al.  Effect of the cholesterol content of small unilamellar liposomes on their stability in vivo and in vitro. , 1980, The Biochemical journal.

[12]  R. Schiffelers,et al.  Therapeutic Application of Long-Circulating Liposomal Glucocorticoids in Auto-Immune Diseases and Cancer , 2006, Journal of liposome research.

[13]  M. Bally,et al.  Influence of vesicle size, lipid composition, and drug-to-lipid ratio on the biological activity of liposomal doxorubicin in mice. , 1989, Cancer research.

[14]  S. Lim,et al.  The Effect of Cholesterol in the Liposome Bilayer on the Stabilization of Incorporated Retinol , 2005, Journal of liposome research.

[15]  M Murdock,et al.  Quality by design. , 1994, Journal of healthcare materiel management.

[16]  Sarfaraz K. Niazi Pharmaceutical Development , 2019, Handbook of Pharmaceutical Manufacturing Formulations.

[17]  Lishuang Xu,et al.  Injectable nimodipine-loaded nanoliposomes: preparation, lyophilization and characteristics. , 2011, International journal of pharmaceutics.

[18]  V. Torchilin,et al.  Drug targeting. , 2000, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.

[19]  Jaiprakash N. Sangshetti,et al.  Quality by design approach: Regulatory need , 2017 .

[20]  René Holm,et al.  Q8(R2): Pharmaceutical Development , 2017 .

[21]  D. Papahadjopoulos,et al.  Optimizing liposomes for delivery of chemotherapeutic agents to solid tumors. , 1999, Pharmacological reviews.

[22]  Antonio P. Costa,et al.  Application of quality by design to formulation and processing of protein liposomes. , 2012, International journal of pharmaceutics.

[23]  R. Schiffelers,et al.  Liposome-encapsulated prednisolone phosphate inhibits growth of established tumors in mice. , 2005, Neoplasia.

[24]  Olaf S Andersen,et al.  Bilayer thickness and membrane protein function: an energetic perspective. , 2007, Annual review of biophysics and biomolecular structure.

[25]  R. Schiffelers,et al.  Antitumor activity of liposomal prednisolone phosphate depends on the presence of functional tumor-associated macrophages in tumor tissue. , 2008, Neoplasia.

[26]  A. Gabizon Stealth liposomes and tumor targeting: one step further in the quest for the magic bullet. , 2001, Clinical cancer research : an official journal of the American Association for Cancer Research.

[27]  R. Schiffelers,et al.  Liposomal glucocorticoids as tumor-targeted anti-angiogenic nanomedicine in B16 melanoma-bearing mice , 2008, The Journal of Steroid Biochemistry and Molecular Biology.

[28]  Buket Aksu,et al.  Quality by design case study 1: Design of 5-fluorouracil loaded lipid nanoparticles by the W/O/W double emulsion - Solvent evaporation method. , 2016, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.

[29]  G. Mugnai,et al.  Enhancement of Nitric Oxide Release in Mouse Inflammatory Macrophages Co-cultivated with Tumor Cells of a Different Origin , 2005, Clinical & Experimental Metastasis.

[30]  Kiran Karande,et al.  Applying quality by design (QbD) concept for fabrication of chitosan coated nanoliposomes , 2014, Journal of liposome research.

[31]  M. Khan,et al.  Predicting hydrophilic drug encapsulation inside unilamellar liposomes. , 2012, International journal of pharmaceutics.

[32]  Nils B. Vogt Quality by design managing research and development , 1992 .

[33]  Sandipan Roy,et al.  Quality by design : A holistic concept of building quality in pharmaceuticals , 2012 .

[34]  C. Rhodes,et al.  Preparation and characterization of liposomes as therapeutic delivery systems: a review. , 1995, Pharmaceutica acta Helvetiae.

[35]  D. Muntean,et al.  Optimizing long-circulating liposomes for delivery of simvastatin to C26 colon carcinoma cells , 2015, Journal of liposome research.

[36]  Lawrence X. Yu Pharmaceutical Quality by Design: Product and Process Development, Understanding, and Control , 2008, Pharmaceutical Research.

[37]  P. D. Drummond,et al.  QUANTUM THEORY OF DISPERSIVE ELECTROMAGNETIC MODES , 1998 .

[38]  M. M. Bradford A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. , 1976, Analytical biochemistry.

[39]  L. Patras,et al.  Liposomal simvastatin inhibits tumor growth via targeting tumor-associated macrophages-mediated oxidative stress. , 2015, Cancer letters.

[40]  Alberto Mantovani,et al.  Transcriptional Profiling of the Human Monocyte-to-Macrophage Differentiation and Polarization: New Molecules and Patterns of Gene Expression1 , 2006, The Journal of Immunology.

[41]  Hervé Broly,et al.  Application of the quality by design approach to the drug substance manufacturing process of an Fc fusion protein: towards a global multi-step design space. , 2012, Journal of pharmaceutical sciences.

[42]  W. Pan,et al.  Fabrication of Carvedilol Nanosuspensions Through the Anti-Solvent Precipitation–Ultrasonication Method for the Improvement of Dissolution Rate and Oral Bioavailability , 2012, AAPS PharmSciTech.

[43]  Mark E. Davis,et al.  Nanoparticle therapeutics: an emerging treatment modality for cancer , 2008, Nature Reviews Drug Discovery.

[44]  R. Cavalli,et al.  Thymopentin in solid lipid nanoparticles , 1996 .

[45]  Michael Glodek,et al.  Process Robustness - A PQRI White Paper , 2006 .